Boeing stock pops on 737 MAX 10 FAA step — what to watch before Monday’s open
11 January 2026
2 mins read

Boeing stock pops on 737 MAX 10 FAA step — what to watch before Monday’s open

New York, Jan 11, 2026, 16:32 EST — Market closed.

  • Boeing shares rose 3.1% on Friday following the 737 MAX 10’s advance into a new FAA flight-test phase.
  • The FAA issued a proposed directive addressing cracking in older 737NG wing structures, with a deadline for comments set for Feb. 26.
  • Focus shifts to Boeing’s Jan. 27 earnings for fresh details on certification, deliveries, and cash flow.

Boeing (NYSE: BA) shares jumped 3.1% to close at $234.53 on Friday after a source close to the program revealed the Federal Aviation Administration has greenlit the 737 MAX 10 — which boasts over 1,200 orders — to enter the second phase of certification flight tests. The approval came despite an unresolved engine de-icing problem; both Boeing and the FAA declined to comment. “It’s progress, but until the MAX 10 is certified, it’s not,” said Scott Hamilton, aerospace analyst at Leeham, noting Boeing still lacks a clear route to begin MAX 10 production at its Everett, Washington plant. (Reuters)

The MAX 10 is crucial to Boeing’s narrowbody comeback, and investors remain focused on whether the company can convert approvals into actual deliveries. In commercial aerospace, cash flow tracks handovers—not test flights.

The FAA process is technical, but from an investor’s perspective, it boils down to one thing: certification is the gatekeeper. Without it, Boeing can’t deliver the MAX 10 to airlines or kick off the full production schedule it’s laid out.

Boeing secured FAA approval to boost 737 MAX production to 42 jets monthly, aiming to tackle airline shortages and ramp up after years of tight supply. What’s left now is getting the green light for the still-uncertified models, like the MAX 10, to join that increase. (Reuters)

Regulators issued a fresh warning this weekend about legacy fleets throwing unexpected challenges. The FAA proposed a new airworthiness directive targeting Boeing 737-700, -800, -900, and -900ER models following reports of cracks in the outward lower wing skin. The directive mandates inspections and ongoing checks, with comments open until Feb. 26. (Federal Register)

An airworthiness directive is a safety order requiring operators to inspect, repair, or replace specific parts. It doesn’t directly challenge Boeing’s MAX certification push but keeps scrutiny on engineering fixes and regulatory oversight—right when Boeing can least afford setbacks.

The bigger risk remains timing. Should the de-icing issue trigger additional redesigns or testing, certification could be delayed once more, shifting deliveries and cash flows further down the line—and giving Airbus an edge in the fiercely competitive single-aisle sector.

On Friday, Boeing was a major contributor to the Dow’s climb, underscoring how sensitive the stock is to even small updates on its programs. (MarketWatch)

Boeing is set to report its fourth-quarter results on Tuesday, Jan. 27. CEO Kelly Ortberg and CFO Jay Malave will review the numbers and outlook during a 10:30 a.m. ET call. (Boeing Investors)

Analysts polled by Yahoo Finance forecast Boeing will post a 42-cent per share loss in its upcoming report. Investors will zero in on any updated timelines for the MAX 10 and MAX 7 models, along with management’s take on delivery trends and cash flow prospects heading into 2026. (Yahoo Finance)

Markets reopen Monday, with investors watching closely for progress on the FAA testing step and signs of a clearer certification path. Boeing’s earnings report and call on Jan. 27 will be the next major catalyst.

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
PepsiCo stock faces CPI week test as rate bets and Feb. 3 earnings loom
Previous Story

PepsiCo stock faces CPI week test as rate bets and Feb. 3 earnings loom

Intuit stock heads into tax-season test as IRS sets Jan. 26 start; insiders file moves
Next Story

Intuit stock heads into tax-season test as IRS sets Jan. 26 start; insiders file moves

Go toTop